Diaceutics PLC Notice of Interim Results and Presentations (3187L)
September 05 2023 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 3187L
Diaceutics PLC
05 September 2023
Notice of Interim Results and Presentations
Belfast and London, 5 September 2023 - Diaceutics PLC (AIM:
DXRX) , a leading technology and solutions provider to the
pharmaceutical industry, today confirms that it will announce its
unaudited results for the six months ended 30 June 2023 on Tuesday,
26 September 2023.
Analyst Presentation
A webinar presentation for analysts will be held at 10.00am on
Tuesday, 26 September 2023 via the London Stock Exchange's
SparkLive platform. Those wishing to attend can register using the
following link:
https://www.lsegissuerservices.com/spark/Diaceutics/events/3e138a9b-2f9d-4adf-b5e0-790cb1f39b49
Investor Presentation
Peter Keeling (CEO), Nick Roberts (CFO) and Ryan Keeling (CIO)
will also provide a live presentation relating to the Company's
results via the Investor Meet Company platform on Tuesday 26
September 2023 at 4.30pm.
The presentation is open to all existing and potential
shareholders and registration can be completed via the following
link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9.00am the day before the meeting or at
any time during the live presentation. Investors who already follow
Diaceutics on the Investor Meet Company platform will automatically
be invited.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Tel: +44 (0)28 9040
6500
Ryan Keeling, Chief Innovation Officer investorrelations@diaceutics.com
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real-world healthcare
data insights, advisory services and innovative platform enabled
solutions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUPUWABUPWGWC
(END) Dow Jones Newswires
September 05, 2023 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024